Yang JC - Search Results

1

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA. Morgan RA, et al. Among authors: yang jc. J Immunother. 2013 Feb;36(2):133-51. doi: 10.1097/CJI.0b013e3182829903. J Immunother. 2013. PMID: 23377668 Free PMC article. Clinical Trial.

2

Clinical application of IL6 in cancer therapy.

Mulé JJ, Marcus SG, Yang JC, Weber JS, Rosenberg SA. Mulé JJ, et al. Among authors: yang jc. Res Immunol. 1992 Sep;143(7):777-9. doi: 10.1016/0923-2494(92)80023-e. Res Immunol. 1992. PMID: 1439156 Clinical Trial. No abstract available.

3

A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy.

Lange JR, Raubitschek AA, Pockaj BA, Spencer WF, Lotze MT, Topalian SL, Yang JC, Rosenberg SA. Lange JR, et al. Among authors: yang jc. J Immunother (1991). 1992 Nov;12(4):265-71. doi: 10.1097/00002371-199211000-00007. J Immunother (1991). 1992. PMID: 1477077 Clinical Trial.

4

Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy.

Sherry RM, Pass HI, Rosenberg SA, Yang JC. Sherry RM, et al. Among authors: yang jc. Cancer. 1992 Apr 1;69(7):1850-5. doi: 10.1002/1097-0142(19920401)69:7<1850::aid-cncr2820690729>3.0.co;2-i. Cancer. 1992. PMID: 1551067 Clinical Trial.

5

The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma.

Weber JS, Yang JC, Topalian SL, Schwartzentruber DJ, White DE, Rosenberg SA. Weber JS, et al. Among authors: yang jc. J Clin Oncol. 1992 Jan;10(1):33-40. doi: 10.1200/JCO.1992.10.1.33. J Clin Oncol. 1992. PMID: 1727923

6

Relapse after response to interleukin-2-based immunotherapy: patterns of progression and response to retreatment.

Sherry RM, Rosenberg SA, Yang JC. Sherry RM, et al. Among authors: yang jc. J Immunother (1991). 1991 Oct;10(5):371-5. doi: 10.1097/00002371-199110000-00009. J Immunother (1991). 1991. PMID: 1790145

7

Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer.

Yang JC, Schwarz SL, Perry-Lalley DM, Rosenberg SA. Yang JC, et al. Lymphokine Cytokine Res. 1991 Dec;10(6):475-80. Lymphokine Cytokine Res. 1991. PMID: 1804310

8

An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity.

Yang JC, Perry-Lalley D, Rosenberg SA. Yang JC, et al. J Biol Response Mod. 1990 Apr;9(2):149-59. J Biol Response Mod. 1990. PMID: 1971302

9

Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response.

Aebersold P, Hyatt C, Johnson S, Hines K, Korcak L, Sanders M, Lotze M, Topalian S, Yang J, Rosenberg SA. Aebersold P, et al. J Natl Cancer Inst. 1991 Jul 3;83(13):932-7. doi: 10.1093/jnci/83.13.932. J Natl Cancer Inst. 1991. PMID: 2067036 Clinical Trial.

10

Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.

Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL, et al. Rosenberg SA, et al. Among authors: yang jc. N Engl J Med. 1990 Aug 30;323(9):570-8. doi: 10.1056/NEJM199008303230904. N Engl J Med. 1990. PMID: 2381442 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,716 results

Search Page